RegulatoryOfficial

FDA approves Lembaz, first drug shown to extend survival in infantile-onset Niemann-Pick type C

🇺🇸 FDA · Tue 17 Nov 2026

Adrabetadex, an intrathecal injection with a boxed warning for hearing impairment, is cleared for patients weighing at least 7 kg whose neurological symptoms began before age 6.

The US Food and Drug Administration has approved Lembaz (adrabetadex) injection to reduce the risk of death in adult and paediatric patients with Niemann-Pick disease type C (NPC). Eligible patients must weigh at least 7 kg (about 15 lb) and have had neurological symptoms begin before age 6, known as infantile-onset NPC. The agency describes it as the first treatment shown to help people with this severe form of the disease live longer.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA ↗

Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.